90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2009

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
NeuroblastomaNeuroendocrine Tumor
Interventions
DRUG

Retinoic Acid

160 mg, given orally, divided BID on Days 1-4 of each cycle for 4 cycles. Each cycle will be six weeks in duration. Dose will be adjusted to 5.33 mg/kg/day divided BID for children \<12 kg.

DRUG

Placebo

Placebo will be given in the same manner as retinoic acid in capsules that look identical.

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

All Listed Sponsors
collaborator

Molecular Insight Pharmaceuticals, Inc.

INDUSTRY

lead

University of Iowa

OTHER